The new year has been a busy one in the world of kidney care. Medicare changes have brought more medications under the payment bundle, insurance coverage and copays are changing for patients, and new options for transplant are being explored.
Advertisement
The KidneyVault Portable Renal Perfusion System has been used in human kidney transplants for the first time.
The 12-member board will guide the guide the patient-driven organization’s research and strategic priorities.
The study is comparing ivonescimab plus platinum-based chemotherapy with tislelizumab plus platinum-based chemotherapy.
The CardioNerds and Dr. Robert Mentz discuss the important steps in treating HF with mineralocorticoid antagonists.
A study compared the risks of cardiovascular events in hospital settings among patients with CKD with and hyperkalemia.
Eli Lilly ended a phase II trial of volenrelaxin in chronic kidney disease "due to a lack of foreseeable clinical benefit."
In the phase II TRANSCEND FL trial the CAR T-cell therapy has shown good efficacy and manageable safety in MZL and FL.
Travere will submit an application to the FDA requesting approval of sparsentan for focal segmental glomerulosclerosis.
Advertisement
DocWire Content Partners
Gain insights from The CardioNerds, a group of cardiology experts who aim to democratize cardiovascular education.
Fundamentals, core concepts, and important management approaches in the field of hematology and oncology
Dr. Chadi Nabhan, a renowned voice in hematology and oncology, tackles a multitude of relevant health care topics.
Drs. Rohit Gosain and Rahul Gosain discuss practice-changing data and standards of oncology care.
Dr. Hady Lichaa is an interventional cardiologist specializing in complex coronary interventions.
Review important issues in the rheumatology space, including lupus, rheumatoid arthritis, and more, from Dr. Maheswaranathan.
Powered by DocWire News
The Latest From GI Oncology Now
Dr. Cytryn summarizes a trial in progress investigating a novel immunotherapy combination for gastroesophageal adenocarcinoma
Drs. Finn and Yopp discuss the challenges of defining high-risk patient populations in adjuvant therapy trials for HCC.
Nivolumab plus ipilimumab provided a higher OS and ORR rate, supporting the combination as a potential standard of care.
The combination was shown to provide a 71% response rate, pointing to a new potential treatment for this patient population.
With an OS rate of about 80%, encorafenib and cetuximab with FOLFOX may serve as a new FDA-approved frontline regimen.
Patients with locally advanced GC who achieved pCR after NAC had significantly better survival outcomes.
The Latest From Heme Today
In the phase II TRANSCEND FL trial the CAR T-cell therapy has shown good efficacy and manageable safety in MZL and FL.
The menin inhibitor oral agent achieved the KOMET-001 trial's primary endpoints and had a favorable benefit-risk profile.
An expert panel's review finds SCT has often been misattributed as the direct cause of mortality in patients who have SCT.
A study cohort with severe disease over a median follow-up of 14 months had an annualized bleeding rate of zero.
Use is also being explored for T-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and mantle cell lymphoma.
Clinicians can use this test to help distinguish more than 60 disease subtypes from patients' normal immune response.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.